Abbott To Take mAbxience Biosimilars To Emerging Markets From 2025
Builds On Initial 2018 Agreement While Aligning With Fresenius Kabi’s 2026 Vision
European biosimilars specialist mAbxience will hand several of its biosimilars over to the global commercialization expertise of Abbott under a new agreement signed between the firms.
